Research has indicated that the activation of inducible nitric oxide synthase (iNOS) and interleukin-6 (IL-6) has the potential to elevate the risk of genetic modification and contribute to the advancement of chemoresistance and tumor progression [22,23]. The gene discussed is NOS2; the disease is neoplasm.